Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

被引：0
|
作者：
Spital, Aaron [1 ]
机构：
[1] St Lukes Roosevelt Hosp, New York, NY 10025 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 368卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1257 / 1257
页数：1
相关论文
共 50 条
  • [41] Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Raina, Rupesh
    Houry, Ahmad
    Rath, Pratik
    Mangat, Guneive
    Pandher, Davinder
    Islam, Muhammad
    Khattab, Ala'a Grace
    Kalout, Joseph K.
    Bagga, Sumedha
    DRUG HEALTHCARE AND PATIENT SAFETY, 2022, 14 : 147 - 159
  • [42] Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
    Hiroko Iijima
    Toshifumi Tada
    Mariko Hashimoto
    Takashi Nishimura
    Masato Kiriki
    Akiko Higashiura
    Aya Iwasaki
    Michino Honda
    Yasuyuki Nagasawa
    Koichiro Yamakado
    Journal of Medical Ultrasonics, 2023, 50 : 81 - 87
  • [43] Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
    Sans-Atxer, Laia
    Joly, Dominique
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2018, 11 : 41 - 51
  • [44] Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease
    Cantarelli, Lorenzo
    Valencia, Marta Gutierrez
    Alegria, Leire Leache
    Fernandez, Luis Carlos Sainz
    Lopez, Juan Erviti
    Nicolas, Fernando Gutierrez
    Casariego, Gloria Julia Nazco
    MEDICINA CLINICA, 2024, 163 (01): : 1 - 7
  • [45] Altered Lipid Metabolism in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
    Bargagli, Matteo
    Anderegg, Manuel
    Ferraro, Pietro Manuel
    Fuster, Daniel G.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 160 - 161
  • [46] Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease
    Masahiko Oguro
    Yuta Kogure
    Junichi Hoshino
    Yoshifumi Ubara
    Hiroki Mizuno
    Akinari Sekine
    Masahiro Kawada
    Keiichi Sumida
    Rikako Hiramatsu
    Eiko Hasegawa
    Masayuki Yamanouchi
    Noriko Hayami
    Tatsuya Suwabe
    Naoki Sawa
    Kenmei Takaichi
    Journal of Nephrology, 2018, 31 : 961 - 966
  • [47] Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
    Rodriguez-Espinosa, Diana
    Jesus Broseta, Jose
    Bastida, Carla
    Isabel Alvarez-Mora, Maria
    Nicolau, Carlos
    Alvarez, Cristina
    Agraz-Pamplona, Irene
    Sanchez-Baya, Maya
    Furlano, Monica
    Ruiz, Cesar
    Quintana, Luis F.
    Pineiro, Gaston J.
    Poch, Esteban
    Torra-Balcells, Roser
    Blasco, Miquel
    NEPHRON, 2023, 147 (3-4) : 152 - 157
  • [48] A Case Report of Tuberous Sclerosis and Autosomal Dominant Polycystic Kidney Disease in the Era of Tolvaptan
    Guerra-Torres, Xavier E.
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2023, 18 (03) : 284 - 290
  • [49] Creatine Kinase Elevation in Patients with Autosomal Dominant Polycystic Kidney Disease on Tolvaptan Treatment
    Rodriguez-Espinosa, Diana
    Payan, Elena C.
    Guillen, Elena
    Blasco Pelicano, Josep Miquel
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 393 - 393
  • [50] Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease Randomized Controlled Trial
    Mekahli, Djalila
    Guay-Woodford, Lisa M.
    Cadnapaphornchai, Melissa A.
    Greenbaum, Larry A.
    Litwin, Mieczyslaw
    Seeman, Tomas
    Dandurand, Ann
    Shi, Lily
    Sikes, Kimberly
    Shoaf, Susan E.
    Schaefer, Franz
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (01): : 36 - 46
12345